NO984084L - 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof - Google Patents
4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereofInfo
- Publication number
- NO984084L NO984084L NO984084A NO984084A NO984084L NO 984084 L NO984084 L NO 984084L NO 984084 A NO984084 A NO 984084A NO 984084 A NO984084 A NO 984084A NO 984084 L NO984084 L NO 984084L
- Authority
- NO
- Norway
- Prior art keywords
- amino
- preparation
- pyrimidine derivatives
- compounds
- medicaments containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Den foreliggende oppfinnelse vedrører 4-amino-pyrimidin-derivater med den generelle formel hvor Ra. Rb- A og B er som definert i krav 1, deres tautomerer, deres stereoisomerer og deres salter, spesielt deres fysiologisk akseptable salter med uorganiske eller organiske syrer eller baser, og som har verdifulle farmakologiske egenskaper, særlig en hemmende virkning på signaltransduksjonen formidlet gjennom tyrosin- kinaser, deres anvendelse for behandling av sykdommer, særlig tumorsykdom- mer, og deres fremstilling.The present invention relates to 4-amino-pyrimidine derivatives of the general formula wherein Ra. Rb-A and B are as defined in claim 1, their tautomers, their stereoisomers and their salts, especially their physiologically acceptable salts with inorganic or organic acids or bases, and which have valuable pharmacological properties, in particular an inhibitory effect on the signal transduction mediated through tyrosine. - kinases, their use in the treatment of diseases, especially tumor diseases, and their preparation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1996108631 DE19608631A1 (en) | 1996-03-06 | 1996-03-06 | New (heterocyclyl- pyrimidino or -pyrido)fused pyrimidine derivatives |
| DE19629652A DE19629652A1 (en) | 1996-03-06 | 1996-07-23 | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation |
| PCT/EP1997/001057 WO1997032881A1 (en) | 1996-03-06 | 1997-03-03 | 4-amino pyrimidine derivates, medicaments containing these compounds, their use and process for their production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO984084L true NO984084L (en) | 1998-09-04 |
| NO984084D0 NO984084D0 (en) | 1998-09-04 |
Family
ID=26023531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO984084A NO984084D0 (en) | 1996-03-06 | 1998-09-04 | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0885226A1 (en) |
| JP (1) | JP2000506847A (en) |
| KR (1) | KR19990087550A (en) |
| CN (1) | CN1212695A (en) |
| AU (1) | AU710274B2 (en) |
| BG (1) | BG102708A (en) |
| BR (1) | BR9708312A (en) |
| CA (1) | CA2243994A1 (en) |
| CZ (1) | CZ281798A3 (en) |
| DE (1) | DE19629652A1 (en) |
| EE (1) | EE9800277A (en) |
| HU (1) | HUP9901820A3 (en) |
| IL (1) | IL125404A0 (en) |
| NO (1) | NO984084D0 (en) |
| NZ (1) | NZ331546A (en) |
| PL (1) | PL328771A1 (en) |
| SK (1) | SK120598A3 (en) |
| TR (1) | TR199801749T2 (en) |
| WO (1) | WO1997032881A1 (en) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990082463A (en) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | Quinazolin derivatives as vascular endothelial growth factor inhibitors |
| CN1116286C (en) | 1996-03-05 | 2003-07-30 | 曾尼卡有限公司 | 4-anilinoquinazoline derivatives |
| EP1396489A1 (en) * | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| PT1244647E (en) | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS |
| UA82517C2 (en) * | 2003-06-24 | 2008-04-25 | Ньюросерч А/С | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CA2598489A1 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| WO2010054264A1 (en) | 2008-11-07 | 2010-05-14 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
| EA201100879A1 (en) * | 2008-12-01 | 2012-01-30 | Мерк Патент Гмбх | PYRIDOPYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS |
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
| JP2013510564A (en) | 2009-11-13 | 2013-03-28 | パンガエア ビオテック、ソシエダッド、リミターダ | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
| RU2614254C2 (en) | 2011-08-31 | 2017-03-24 | Дженентек, Инк. | Diagnostic markers |
| EP2761025A1 (en) | 2011-09-30 | 2014-08-06 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| JP6255038B2 (en) | 2013-02-26 | 2017-12-27 | トリアクト セラピューティクス，インク． | Cancer treatment |
| WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
| EP3044593A4 (en) | 2013-09-09 | 2017-05-17 | Triact Therapeutics, Inc. | Cancer therapy |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| CA2969830A1 (en) | 2014-12-24 | 2016-06-30 | Genentech, Inc. | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
| HUE056777T2 (en) | 2016-12-22 | 2022-03-28 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| MA50077A (en) | 2017-09-08 | 2020-07-15 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| MX2020011582A (en) | 2018-05-04 | 2020-11-24 | Amgen Inc | Kras g12c inhibitors and methods of using the same. |
| MA52564A (en) | 2018-05-10 | 2021-03-17 | Amgen Inc | KRAS G12C INHIBITORS FOR CANCER TREATMENT |
| MA52765A (en) | 2018-06-01 | 2021-04-14 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
| AU2019284472B2 (en) | 2018-06-11 | 2024-05-30 | Amgen Inc. | KRAS G12C inhibitors for treating cancer |
| CA3100390A1 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer |
| US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
| JP7516029B2 (en) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| MX2021005700A (en) | 2018-11-19 | 2021-07-07 | Amgen Inc | Kras g12c inhibitors and methods of using the same. |
| MX2021007156A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Kif18a inhibitors. |
| EP3897855B1 (en) | 2018-12-20 | 2023-06-07 | Amgen Inc. | Kif18a inhibitors |
| CA3123227A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| US20220002311A1 (en) | 2018-12-20 | 2022-01-06 | Amgen Inc. | Kif18a inhibitors |
| US20230148450A9 (en) | 2019-03-01 | 2023-05-11 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| JP2022522778A (en) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | Bicyclic heterocyclyl compounds and their use |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| US11236091B2 (en) | 2019-05-21 | 2022-02-01 | Amgen Inc. | Solid state forms |
| JP2022542319A (en) | 2019-08-02 | 2022-09-30 | アムジエン・インコーポレーテツド | KIF18A inhibitor |
| CN114269731A (en) | 2019-08-02 | 2022-04-01 | 美国安进公司 | KIF18A inhibitors |
| WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| MX2022001302A (en) | 2019-08-02 | 2022-03-02 | Amgen Inc | Pyridine derivatives as kif18a inhibitors. |
| MX2022004656A (en) | 2019-10-24 | 2022-05-25 | Amgen Inc | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer. |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2022553859A (en) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | RAS inhibitor |
| WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| US20210139517A1 (en) | 2019-11-08 | 2021-05-13 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| US20230192681A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| MX2022005726A (en) | 2019-11-14 | 2022-06-09 | Amgen Inc | Improved synthesis of kras g12c inhibitor compound. |
| CN114980976A (en) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | Covalent RAS inhibitors and uses thereof |
| AU2021206217A1 (en) | 2020-01-07 | 2022-09-01 | Revolution Medicines, Inc. | SHP2 inhibitor dosing and methods of treating cancer |
| BR112022025550A2 (en) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | METHODS TO DELAY, PREVENT, AND TREAT ACQUIRED RESISTANCE TO RAS INHIBITORS |
| MX2023002248A (en) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations. |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202241885A (en) | 2020-12-22 | 2022-11-01 | 大陸商上海齊魯銳格醫藥研發有限公司 | Sos1 inhibitors and uses thereof |
| PE20240327A1 (en) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | HETEROCYCLES WITH AMINO SUBSTITUTION TO TREAT CANCERS WITH EGFR MUTATIONS |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| PE20240088A1 (en) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | RAS INHIBITORS |
| AR125787A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| TW202340214A (en) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| DE4431867A1 (en) * | 1994-09-07 | 1996-03-14 | Thomae Gmbh Dr K | New 4-amino-pyrimido-pyrimidine derivs. |
-
1996
- 1996-07-23 DE DE19629652A patent/DE19629652A1/en not_active Ceased
-
1997
- 1997-03-03 EE EE9800277A patent/EE9800277A/en unknown
- 1997-03-03 PL PL97328771A patent/PL328771A1/en unknown
- 1997-03-03 IL IL12540497A patent/IL125404A0/en unknown
- 1997-03-03 BR BR9708312A patent/BR9708312A/en not_active IP Right Cessation
- 1997-03-03 KR KR1019980706987A patent/KR19990087550A/en not_active Application Discontinuation
- 1997-03-03 WO PCT/EP1997/001057 patent/WO1997032881A1/en not_active Application Discontinuation
- 1997-03-03 AU AU19251/97A patent/AU710274B2/en not_active Ceased
- 1997-03-03 CZ CZ982817A patent/CZ281798A3/en unknown
- 1997-03-03 CA CA002243994A patent/CA2243994A1/en not_active Abandoned
- 1997-03-03 EP EP97907066A patent/EP0885226A1/en not_active Ceased
- 1997-03-03 TR TR1998/01749T patent/TR199801749T2/en unknown
- 1997-03-03 NZ NZ331546A patent/NZ331546A/en unknown
- 1997-03-03 SK SK1205-98A patent/SK120598A3/en unknown
- 1997-03-03 HU HU9901820A patent/HUP9901820A3/en unknown
- 1997-03-03 CN CN97192787A patent/CN1212695A/en active Pending
- 1997-03-03 JP JP9531444A patent/JP2000506847A/en active Pending
-
1998
- 1998-08-20 BG BG102708A patent/BG102708A/en unknown
- 1998-09-04 NO NO984084A patent/NO984084D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997032881A1 (en) | 1997-09-12 |
| PL328771A1 (en) | 1999-02-15 |
| AU1925197A (en) | 1997-09-22 |
| EE9800277A (en) | 1999-02-15 |
| DE19629652A1 (en) | 1998-01-29 |
| KR19990087550A (en) | 1999-12-27 |
| JP2000506847A (en) | 2000-06-06 |
| EP0885226A1 (en) | 1998-12-23 |
| NZ331546A (en) | 2000-03-27 |
| HUP9901820A2 (en) | 1999-09-28 |
| AU710274B2 (en) | 1999-09-16 |
| CN1212695A (en) | 1999-03-31 |
| CA2243994A1 (en) | 1997-09-12 |
| HUP9901820A3 (en) | 2001-10-29 |
| BR9708312A (en) | 1999-08-03 |
| TR199801749T2 (en) | 1998-12-21 |
| SK120598A3 (en) | 1999-06-11 |
| NO984084D0 (en) | 1998-09-04 |
| BG102708A (en) | 1999-09-30 |
| CZ281798A3 (en) | 1999-02-17 |
| IL125404A0 (en) | 1999-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO984084L (en) | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof | |
| MY123642A (en) | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, and processes for preparing them. | |
| NO984081L (en) | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and method of preparation thereof | |
| CA2375259A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| CA2417897A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| CA2417652A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| CA2432428A1 (en) | Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| BG105765A (en) | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | |
| NO933248L (en) | Cyclic urea derivatives, drugs containing these compounds, and process for their preparation | |
| NO307833B1 (en) | Pyrimido [5,4-d] pyrimidines, physiologically acceptable salts, drugs containing these compounds and their use | |
| NO991732L (en) | New heterocyclylmethyl substituted pyrazole derivatives | |
| CA2417050A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| CA2403152A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| MX9807073A (en) | Pyrimido[5,4-d]pyrimidines, medicaments containing these compounds, their use and process for their production | |
| TW200504067A (en) | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | |
| NO972881L (en) | Piperazine derivatives, drugs containing them, their use and methods for their preparation | |
| NO934501L (en) | Carboxylic acid derivatives, drugs containing these compounds, and process for their preparation | |
| AU2001295482A1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof | |
| WO2000055162A3 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| AU5500896A (en) | Substituted phenylamidines, pharmaceutical compositions containing these compounds and processes for preparing them | |
| MY140484A (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| YU60501A (en) | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |